Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025
DOI: 10.1007/s00210-025-04067-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. Verfasst von Akarsha Balnadupete und 6 weiteren Autor:innen. Beteiligte Einrichtung: Yenepoya Research Centre, Yenepoya (Deemed to Be University), Deralakatte, Mangalore, 575018, Karnataka, India. Hauptthemen laut MEDLINE: NF-kappa B, Pulmonary Fibrosis, Phytochemicals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 193 Literaturangaben.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a slow and irreparable damage of the lung caused by the accumulation of scar tissue, which eventually results in organ dysfunction and fatality from gas exchange failure. One of the extensively studied inflammatory pathways in PF is the NF-κB signalling pathway, which is reportedly involved in epithelial-mesenchymal transition, myofibroblast differentiation, and other cellular processes. Additionally, studies have evidence that NF-κB signalling pathways can be employed as a potential target for developing therapeutic agents against PF. In the current scenario, FDA-approved drugs, nintedanib and pirfenidone, have been used for the treatment of PF with potential side effects. Recently, the usage of bioactive compounds has attracted attention in the treatment of PF. This review focuses on the involvement of the NF-κB signalling pathway in PF and the significance of phytocompounds in regulating the NF-κB pathway. Both the in vitro and in vivo studies reveal that NF-κB-targeted plant-based bioactive compounds significantly ameliorate the PF condition as well as improve the health condition. Databases such as Scopus, PubMed, and Web of Science were used to conduct literature surveys and compile data on all the bioactive compounds. In conclusion, the plant-derived bioactive compounds are potent enough to target the NF-κB with its biological properties, and this could be a highly effective therapeutic strategy for PF in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Yenepoya Research Centre, Yenepoya (Deemed to Be University), Deralakatte, Mangalore, 575018, Karnataka, India.
- Yenepoya Research Centre, Yenepoya (Deemed to Be University), Deralakatte, Mangalore, 575018, Karnataka, India. yashbhandary@yenepoya.edu.in.
- Specialized Research Unit, Yenepoya Medical College & Hospital, Yenepoya (Deemed to Be University), Deralakatte, Mangalore, Karnataka, 575018, India. yashbhandary@yenepoya.edu.in.
Zitieren
APA
Balnadupete, A., Moideen, F. M., Varughese, A., Mugaranja, K., M, J. T., Charavu, R., & Bhandary, Y. (2025). Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04067-1
Vancouver
Balnadupete A, Moideen FM, Varughese A, Mugaranja K, M JT, Charavu R, et al. Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025. doi:10.1007/s00210-025-04067-1
BibTeX
@article{Balnadupete2025,
author = {Balnadupete, Akarsha and Moideen, Fathimath Muneesa and Varughese, Aleena and Mugaranja, Kirana and M, Jeena T and Charavu, Rakshitha and Bhandary, Yashodhar},
title = {Beyond the pill: incrimination of nuclear factor-kappa B and their targeted phytomedicine for pulmonary fibrosis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
doi = {10.1007/s00210-025-04067-1}
}
EUVIMED